Previous 10 | Next 10 |
home / stock / cybn:cc / cybn:cc news
Cybin Inc. ( NEO:CYBN ) ( NYSE American:CYBN ) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” is pleased to announce that Doug Drysdale, Cybin’...
Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam war and is still the preferred anesthetic in battlefield situations...
Intrusive or unwanted thoughts are a common human experience. They often appear out of the blue, and in most cases, they tend to be unpleasant and unwanted. Unwanted thoughts and images can cause distress, especially when they force you to think about past traumatic or distressing events...
Cybin (NEO: CYBN) (NYSE American: CYBN) , a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled its annual shareholder meeting. The company’s 2022 Annual Meeting of Shareholders will begin at 10 a.m. ET on Aug. 15, 2022; the meeting w...
Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” announced today that its 2022 Annual Meeting of Shareholders w...
With speculation about psychedelics at an all-time high and the market projected to grow exponentially in the next few years, psychedelic stocks have been a draw for many investors. However, given that the market is still new and has plenty of legal and regulatory challenges to surpass, in...
Data from newly acquired study could accelerate clinical development of CYBN’s CYB004 by nine months The pivotal study was designed with four primary objectives Cybin’s proprietary substance has potential to effectively treat anxiety disorders, including GAD and SAD ...
Cybin (NYSE American: CYBN) (NEO: CYBN) , a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various conditions, has announced preliminary data from a feasibility study using Kernel Flow. The results indicate that ketamine-induced changes in function...
Research from recent years has revealed that psychedelic drugs have the potential to revolutionize mental health treatment. Psychedelics are federally classified as Schedule I drugs with no medical potential, however, making it nigh impossible for the people who would benefit from psyche...
DMT is said to be one of the most potent hallucinogens known to man. Smoking this drug, which is also called the spirit molecule, can cause a range of hallucinations, including visions of alien landscapes, temples, clowns, fairies, sprites, elves and goddesses. Nick Sand, an underground ...
News, Short Squeeze, Breakout and More Instantly...
CYBIN INC. Company Name:
CYBN:CC Stock Symbol:
AQNC Market:
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting “a swell” of insider purchases followi...
Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update on progress made in fiscal 2024 ending on March 31st. In its presser , Cybin highlighted k...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting its audited financial results for the fiscal year en...